Purpose: Insertion of radiopaque markers is helpful for tumor localization in patients receiving neoadjuvant chemotherapy (NAC) followed by breast-conserving surgery (BCS). The aim of this retrospective study was to investigate the pathologic margin status in patients with single or double marker insertion. Methods: We reviewed the records of 130 patients with marker insertion prior to NAC followed by BCS from January 2016 to September 2019. Under ultrasonography guidance, single or double markers were inserted to localize a tumor in the breast. The incidence of additional resection after frozen biopsy and re-excision after permanent pathologic diagnosis was analyzed. Results: In a total of 130 patients, 104 had a single marker in the center of the tumor and 26 had double markers at the periphery of the tumor before NAC. Among 69 patients with residual invasive tumors after NAC, there was no difference in the additional resection rate after frozen biopsy (single vs. double markers; 14.3% vs. 38.5%, P =.059) or the re-excision rate after final pathologic diagnosis (0% vs. 7.7%, P =.188). After propensity score matching for tumor size and subtypes, the two groups showed no differences in the additional resection rate after frozen biopsy (7.7% vs. 19.2%, P =.139) or the re-excision rate (0% vs. 3.8%, P =.308). After a median follow-up of 19 months (range 8–48 months), local recurrence-free survival did not differ between the two groups (log-rank P =.456). Conclusions: Number of inserted markers for tumor localization did not affect the pathologic margin status after BCS.
Bibliographical noteFunding Information:
The authors would like to thank the Department of Biostatistics, Yonsei University College of Medicine, for assistance in statistical analysis
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
All Science Journal Classification (ASJC) codes
- Cancer Research